Argitalpenak (20) Ikertzaileren baten partaidetza izan duten argitalpenak

2017

  1. A phase II trial of autologous dendritic cell vaccination and radiochemotherapy following fluorescence-guided surgery in newly diagnosed glioblastoma patients

    Journal of Translational Medicine, Vol. 15, Núm. 1

  2. A simple flow-cytometry method to evaluate peripheral blood contamination of bone marrow aspirates

    Journal of Immunological Methods, Vol. 442, pp. 54-58

  3. Anti-CD137 and PD-1/PD-L1 antibodies en route toward clinical synergy

    Clinical Cancer Research, Vol. 23, Núm. 18, pp. 5326-5328

  4. Antibody-dependent cell cytotoxicity: Immunotherapy strategies enhancing effector NK cells

    Immunology and Cell Biology, Vol. 95, Núm. 4, pp. 347-355

  5. Brachytherapy attains abscopal effects when combined with immunostimulatory monoclonal antibodies

    Brachytherapy, Vol. 16, Núm. 6, pp. 1246-1251

  6. Cellular immunotherapies for cancer

    OncoImmunology, Vol. 6, Núm. 5

  7. Changes in serum interleukin-8 (IL-8) levels reflect and predict response to anti-PD-1 treatment in melanoma and non-small-cell lung cancer patients

    Annals of Oncology, Vol. 28, Núm. 8, pp. 1988-1995

  8. First-line use of rituximab correlates with increased overall survival in late post-transplant lymphoproliferative disorders: retrospective, single-centre study

    European Journal of Haematology, Vol. 98, Núm. 1, pp. 38-43

  9. Identification of LAG3 high affinity aptamers by HT-SELEX and Conserved Motif Accumulation (CMA)

    PLoS ONE, Vol. 12, Núm. 9

  10. Impaired HLA class I antigen processing and presentation as a mechanism of acquired resistance to immune checkpoint inhibitors in lung cancer

    Cancer Discovery, Vol. 7, Núm. 12, pp. 1420-1435

  11. Intercellular Adhesion Molecule-1 and Vascular Cell Adhesion Molecule Are Induced by Ionizing Radiation on Lymphatic Endothelium

    International Journal of Radiation Oncology Biology Physics, Vol. 97, Núm. 2, pp. 389-400

  12. Interleukin-8 in cancer pathogenesis, treatment and follow-up

    Cancer Treatment Reviews, Vol. 60, pp. 24-31

  13. Intratumoral delivery of immunotherapy - Act locally, think globally

    Journal of Immunology, Vol. 198, Núm. 1, pp. 31-39

  14. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial

    The Lancet, Vol. 389, Núm. 10088, pp. 2492-2502

  15. Predictors of responses to immune checkpoint blockade in advanced melanoma

    Nature Communications, Vol. 8, Núm. 1

  16. Results from an integrated safety analysis of urelumab, an agonist anti-CD137 monoclonal antibody

    Clinical Cancer Research, Vol. 23, Núm. 8, pp. 1929-1936

  17. Strategies to design clinical studies to identify predictive biomarkers in cancer research

    Cancer Treatment Reviews, Vol. 53, pp. 79-97

  18. T Cell Migration from Inflamed Skin to Draining Lymph Nodes Requires Intralymphatic Crawling Supported by ICAM-1/LFA-1 Interactions

    Cell Reports, Vol. 18, Núm. 4, pp. 857-865

  19. Target Expression, Generation, Preclinical Activity, and Pharmacokinetics of the BCMA-T Cell Bispecific Antibody EM801 for Multiple Myeloma Treatment

    Cancer Cell, Vol. 31, Núm. 3, pp. 396-410

  20. Targeting NK-cell checkpoints for cancer immunotherapy

    Current Opinion in Immunology, Vol. 45, pp. 73-81